Next Article in Journal
Association of Tumor Microenvironment with Biological and Chronological Age in Head and Neck Cancer
Next Article in Special Issue
Induction Fluorouracil-Based Chemotherapy and PET-Adapted Consolidation Chemoradiation with Esophagectomy for High-Risk Gastroesophageal Adenocarcinoma
Previous Article in Journal
Brain Re-Irradiation Robustly Accounting for Previously Delivered Dose
Previous Article in Special Issue
Interpretation of Tumor Response Grade following Preoperative Therapy for Gastric Cancer: An Overview
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 15
Issue 15
10.3390/cancers15153833
Review Report
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Neoadjuvant Immunotherapy for Patients with dMMR/MSI-High Gastrointestinal Cancers: A Changing Paradigm

Cancers 2023, 15(15), 3833; https://doi.org/10.3390/cancers15153833
by Muhammet Ozer 1,†, Charan Thej Reddy Vegivinti 2,†, Masood Syed 3, Morgan E. Ferrell 3, Cyndi Gonzalez Gomez 3, Svea Cheng 3, Jennifer Holder-Murray 4, Tullia Bruno 5, Anwaar Saeed 6 and Ibrahim Halil Sahin 6,*
Reviewer 1:
Moh'd Khusman
Reviewer 2: Anonymous
Reviewer 3: Anonymous
Cancers 2023, 15(15), 3833; https://doi.org/10.3390/cancers15153833
Submission received: 5 July 2023 / Revised: 19 July 2023 / Accepted: 25 July 2023 / Published: 28 July 2023
(This article belongs to the Special Issue Clinical and Pathologic Response to Therapy in Gastrointestinal Oncology)

Round 1

Reviewer 1 Report

In this paper, the authors nicely summarized a changing paradigm related to neoadjuvant immunotherapy for patients with dMMR/MSI-H GI cancers.  Congratulations!

The paper is well written and very comprehensive covering the existing literature and ongoing trials that are exploring the role of neoadjuvant IO in GI malignancies.   

Author Response

Thank you very much for the kind comments and endorsing our manuscript for publications! 

Reviewer 2 Report

In this review article, the authors provide an overview of recent advancements in neoad-juvant immunotherapy for patients with dMMR/MSI-H gastrointestinal cancers, they also elaborate on the advantages and challenges of neoadjuvant ICI therapy.

 

This is a comprehensive review, giving a great overview of the available literature. The topic of the review is suitable for this special issue and is of interest for the readership of this journal. The manuscript has been written well, the flow of ideas information and ideas are acceptable. The manuscript have scientific merit for publication. Therefore, I would like to suggest to accept in the present form.

Author Response

Thanks for your kind and thoughtful comments. We appreciate your endorsement for acceptance of our manuscript for publication. 

Reviewer 3 Report

This review discusses the use of immune checkpoint inhibitors (ICI) in clinical studies for the treatment of gastrointestinal cancers with a mismatch repair deficiency (MMR-D)/microsatellite instability-high (MSI-H). The use of ICIs has shown great promise with a strong impact on current cancer treatment. The review is well-written and easy to understand. One suggestion for improvement would be for the authors to briefly summarize the differences in the immune microenvironment, such as T cell infiltration, between MSI-H and MSS CRC. Additionally, it would be beneficial to include a discussion on the physiological and metabolic changes of T-cells in response to ICI. Some more recent publications (e.g., 10.1016/j.celrep.2022.111929; 10.1126/scitranslmed.add1016; 10.1016/j.ccell.2023.04.011; 10.1158/1078-0432.CCR-21-0163) could provide useful insights.

Author Response

Thanks so much for this insightful comments. We have now added another paragraph to discussion to address importance of the tumor microenvironment and discussed recent multi-omic studies suggested by the Reviewer and cited in the article. We thank so much again for this important feedback.

Author Response File: Author Response.docx

Round 2

Reviewer 3 Report

Excellent work.

Back to TopTop